Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Transradial access (TRA) is the preferred vascular access site for invasive coronary
angiography. TRA is limited by blockage of the radial artery post-procedurally, preventing
future use of TRA. This is referred to as radial artery occlusion (RAO) and occurs in ~5% of
cases. While intraprocedural anticoagulation has been studied extensively to mitigate this
complication, oral anticoagulation post-TRA has not. We will assess the impact of a one-week
course of rivaroxaban post-TRA to reduce the rate of ultrasound-defined RAO at 30 days.